40 41 In a recent meta-analysis of RAPIDS-1 and RAPIDS-2, treatment with bosentan was associated with a significant reduction in the mean number of new DUs per patient in the overall trial population (SMD; 95% CI −0.34; −0.57 to −0.11, p=0.004) and in patients with SSc with baseline DUs (SMD; 95% CI −0.36; −0.61 to −0.11, p=0.005).